Malcolm McComas

Mr. McComas brings 25 years of investment banking experience in M&A, debt and equity funding across multiple industry sectors. He previously held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this, he was a tax lawyer.

Mr. McComas is also an experienced company director and currently serves as Chairman of Pharmaxis (ASX: PXS) and Fitzroy River Corporation (ASX:FZR) and as a director of Core Lithium (ASX: CXO). He was previously a director of BCI Minerals (ASX:BCI), Saunders International (ASX: SND) and other entities.

Mr. McComas is also a director the Australasian Leukemia and Lymphoma clinical trials group (ALLG) and a former president of the Financial Services Institute of Australia (FINSIA).  He is a Fellow of the Australian Institute of Company Directors and holds degrees in Law and Economics from Monash University in Melbourne.

LinkedIn Profile: https://www.linkedin.com/in/malcolmmccomas

Dr. George Morstyn

Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had overall responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn’s tenure. Prior to joining Amgen Inc., Dr Morstyn was the principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (‘CSFs’). The CSFs were subsequently approved and launched and were a major medical breakthrough that have been used to reduce side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide. The CSFs have become multi-billion dollar drugs. Since returning to Australia, Dr Morstyn has been a Non-Executive Director of various for-profit and not for profit companies, including many biotechnology companies.

Dr Morstyn is a medical graduate of Monash University (Australia), and obtained a PhD at the Walter and Eliza Hall Institute of Medical Research (Australia) and a FRACP in Medical Oncology following a Fellowship at the National Cancer Institute in the USA. He is a Member of the Australian Institute of Company Directors and a Fellow of the Australian Academy of Technological Sciences and Engineering.

LinkedIn Profile: linkedin.com/in/george-morstyn-ftse-fracp-6833a24

Dr. Bill Ketelbey

Dr Ketelbey has more than 30 years’ experience in the healthcare, biotech and pharmaceutical industries, including senior medical and management roles in the Asia Pacific Region with global pharmaceutical company Pfizer.

Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. Dr Ketelbey led the local clinical development, and was involved in the commercialisation, of Aricept™ (donepezil), the market-leading Alzheimer’s disease therapy.

Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa and a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom. He also has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.

Dr. Ketelbey is also a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and chairs the IP and Commercialisation Committee of WIMR.

LinkedIn Profile: linkedin.com/in/bill-ketelbey-0032098a

Twitter: @BillKetelbey https://twitter.com/billketelbey

DR. Geoff Brooke

Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years’ experience in the healthcare investment industry. He was the founder and managing director of two venture capital firms, Medvest Inc and GBS Venture Partners, which is viewed as one of the Asia Pacific region’s premier healthcare venture investors.

Dr Brooke has been a major investor, chairman or director of companies in the healthcare sector with a combined realised value of $1.5 billion. Dr Brooke’s expertise includes assisting high growth technology-based companies in areas such as development strategy, clinical trial design, fund raising, management structuring and investment exits.

Dr Brooke is a medical graduate of the University of Melbourne and has an MBA from IMEDE (now IMD), Lausanne Switzerland.